[The immunogenicity of the hepatitis B vaccine in drug addicts with human immunodeficiency virus infection].
In order to evaluate the antibody response to anti-hepatitis B vaccine, 21 heroin addicted with HIV infection previously vaccinated, were studied. 18 patients were asymptomatic and 3 were at the LAS stage. An antibody response was estimated at 1 and 12 months after the end of the vaccination. The first control showed that 62% presented a protective anti-HBs (higher than 10 mU/ml); after one year 70% of responders had a persistent immunity. The antibody response showed no correlation with the value of immunologic tests; the vaccine showed neither a significant evidence of side-effects nor a negative influence on the HIV infection.
Menicagli
V
V
Divisione Malattie infettive, Spedali riuniti, Livorno.
Barbanera
M
M
Menicagli
S
S
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000276:immunology*; D006679:HIV Seropositivity / Q000150:complications / Q000276:immunology; D015497:HIV-1; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood; D006556:Heroin Dependence / Q000150:complications / Q000276:immunology*; D006801:Humans; D013997:Time Factors; D014761:Viral Hepatitis Vaccines / Q000276:immunology*
D006510:Hepatitis B Antibodies; D014761:Viral Hepatitis Vaccines
Immunogenicità del vaccino anti-epatite B in tossicodipendenti con infezione da virus dell'immunodeficienza umana.